Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 6/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17134809 | 0.96 | FASN (0.38) | FASNRBP4GAAALDH1A1PIK3C3 | |
| SCHEMBL17135077 | 0.94 | FASN (0.38) | FASNGAAALDH1A1PRSS12SCN8A | |
| SCHEMBL17135109 | 0.93 | FASN (0.39) | FASNALDH1A1SCN9ASCN8ATRPC6 | |
| SCHEMBL17134505 | 0.92 | FASN (0.38) | FASNALDH1A1PRSS12TRPC6 | |
| SCHEMBL17135096 | 0.91 | FASN (0.38) | FASNALDH1A1PIK3C3SCN9ASCN8A | |
| SCHEMBL17134623 | 0.91 | MAPT (0.39) | FASNRBP4GAAALDH1A1PIK3C3 | |
| SCHEMBL17135220 | 0.90 | FASN (0.39) | FASNALDH1A1SCN9A | |
| SCHEMBL17134605 | 0.90 | SCN8A (0.36) | FASNSCN9ASCN8AHSD11B1 | |
| SCHEMBL17135195 | 0.90 | FASN (0.38) | FASNPIK3C3SCN9ASCN8ATRPC6 | |
| SCHEMBL17134636 | 0.90 | FASN (0.38) | FASNALDH1A1PIK3C3SCN9APRSS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927214-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9701689-B2 | Substituted pyridines and pyridazines as CCR10 receptor inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2927214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299214-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | ARG1, H1-0, TYR | FASN 4391/4885RBP4 3290/4885GAA 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.